Protagonist Therapeutics (PTGX) Selects Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 5/28/2022

1. SPY
2. WDAY
3. COST
4. ZS
5. MRVL
6. DELL
7. GPS
8. ULTA
9. AEO
10. ADSK

Go back to Protagonist Therapeutics (PTGX) Selects Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
(NASDAQ: PTGX) Delayed: 8.90 +0.59 (7.10%)
Previous Close $8.31    52 Week High $24.52 
Open $8.35    52 Week Low $10.02 
Day High $8.90    P/E N/A 
Day Low $8.21    EPS $0.00 
Volume 713,764